Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet all of the following inclusion criteria:~* Voluntary written consent~* Male patients 18 years or older~* Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma~* Radiograph-documented metastatic disease~* Progressive disease~* Prior surgical castration or concurrent use of an agent for medical castration~* Either absence of pain or pain not requiring use of any opioid or narcotic analgesia in the 2 weeks prior to study entry~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Even if surgically sterilized, patients must practice effective barrier contraception during the entire study treatment and for 4 months after the last dose of study drug, OR abstain from heterosexual intercourse~* Meet screening laboratory values as specified in protocol~* Stable medical condition~Exclusion Criteria:~Patients meeting any of the following exclusion criteria are not to be enrolled in the study:~* Known hypersensitivity to orteronel, prednisone or gonadotropin-releasing hormone (GnRH) analogue~* Received prior therapy with orteronel, aminoglutethimide, ketoconazole or abiraterone~* Received antiandrogen therapy within 6 weeks for bicalutamide and 4 weeks for all others prior to first dose of study drug~* Continuous daily use of oral prednisone or oral dexamethasone for more than 14 days within 3 months prior to study~* Received prior chemotherapy for prostate cancer with exception of neoadjuvant/adjuvant therapy as part of initial primary treatment for local disease that was completed 2 or more years prior to screening~* Exposure to radioisotope therapy within 4 weeks of receiving first dose of study drug; exposure to external beam radiation within 2 weeks of start of screening until receiving the first dose of study drug~* Documented central nervous system metastases~* Treatment with any investigational compound within 30 days prior to first dose of study drug~* Current spinal cord compression, bilateral hydronephrosis or current bladder neck outlet obstruction~* Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected~* Uncontrolled cardiovascular condition as specified in study protocol~* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C~* Unwilling or unable to comply with protocol~* Uncontrolled nausea, vomiting or diarrhea~* Known gastrointestinal disease or procedure that could interfere with oral absorption or tolerance of orteronel

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orteronel + prednisone (Type: EXPERIMENTAL): None
- Placebo + prednisone (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).